•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.

Inclusion Criteria:

• Signed Informed Consent Form (ICF).
• Aged 18 years or older.
• Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
• Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to radical surgery.
• ECOG Performance Status of 0 or 1.
• Child-Pugh class of A.

Exclusion Criteria:

• Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously.
• Existence of active autoimmune disease or history of autoimmune disease and may relapse.
• Patients with innate or acquired immune deficiency (e.g., HIV infection).
• Known allergies to study drugs or excipients.